Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10312640" target="_blank" >RIV/00216208:11110/15:10312640 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00843989:_____/15:E0105213 RIV/00064165:_____/15:10312640
Výsledek na webu
<a href="http://dx.doi.org/10.1056/NEJMoa1501917" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1501917</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1501917" target="_blank" >10.1056/NEJMoa1501917</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia
Popis výsledku v původním jazyce
BACKGROUND Systemic glucocorticoids reduce the incidence of bronchopulmonary dysplasia among extremely preterm infants, but they may compromise brain development. The effects of inhaled glucocorticoids on outcomes in these infants are unclear. METHODS Werandomly assigned 863 infants (gestational age, 23 weeks 0 days to 27 weeks 6 days) to early (within 24 hours after birth) inhaled budesonide or placebo until they no longer required oxygen and positive-pressure support or until they reached a postmenstrual age of 32 weeks 0 days. The primary outcome was death or bronchopulmonary dysplasia, confirmed by means of standardized oxygen-saturation monitoring, at a postmenstrual age of 36 weeks. RESULTS A total of 175 of 437 infants assigned to budesonide for whom adequate data were available (40.0%), as compared with 194 of 419 infants assigned to placebo for whom adequate data were available (46.3%), died or had bronchopulmonary dysplasia (relative risk, stratified according to gestational
Název v anglickém jazyce
Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia
Popis výsledku anglicky
BACKGROUND Systemic glucocorticoids reduce the incidence of bronchopulmonary dysplasia among extremely preterm infants, but they may compromise brain development. The effects of inhaled glucocorticoids on outcomes in these infants are unclear. METHODS Werandomly assigned 863 infants (gestational age, 23 weeks 0 days to 27 weeks 6 days) to early (within 24 hours after birth) inhaled budesonide or placebo until they no longer required oxygen and positive-pressure support or until they reached a postmenstrual age of 32 weeks 0 days. The primary outcome was death or bronchopulmonary dysplasia, confirmed by means of standardized oxygen-saturation monitoring, at a postmenstrual age of 36 weeks. RESULTS A total of 175 of 437 infants assigned to budesonide for whom adequate data were available (40.0%), as compared with 194 of 419 infants assigned to placebo for whom adequate data were available (46.3%), died or had bronchopulmonary dysplasia (relative risk, stratified according to gestational
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FP - Ostatní lékařské obory
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/7E09060" target="_blank" >7E09060: Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
New England Journal of Medicine
ISSN
0028-4793
e-ISSN
—
Svazek periodika
373
Číslo periodika v rámci svazku
16
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
10
Strana od-do
1497-1506
Kód UT WoS článku
000362880300006
EID výsledku v databázi Scopus
2-s2.0-84944463128